AAP
PCVX icon

Arax Advisory Partners’s Vaxcyte PCVX Stock Holding History

Arax Advisory Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8K Buy
393
+289
+278% +$15.7K ﹤0.01% 3867
2026
Q1 		$6.04K Buy
104
+12
+13% +$651 ﹤0.01% 2696
2025
Q4 		$4.25K Sell
92
-82
-47% -$3.67K ﹤0.01% 2943
2025
Q3 		$6.27K Buy
174
+4
+2% +$133 ﹤0.01% 2792
2025
Q2 		$5.53K Buy
+170
New +$5.57K ﹤0.01% 2213
2025
Q1 		– Sell
-65
Closed -$5.32K – 2949
2024
Q4 		$5.32K Buy
65
+4
+7% +$397 ﹤0.01% 1720
2024
Q3 		$6.97K Buy
61
+9
+17% +$811 ﹤0.01% 1560
2024
Q2 		$3.93K Buy
+52
New +$3.54K ﹤0.01% 1698

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arax Advisory Partners's PCVX Position: Q2 2026 in Review

Arax Advisory Partners increased its Vaxcyte (PCVX) stake by 278% in Q2 2026, buying an estimated $15.7K and bringing the position to 393 shares worth $22.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3867.

Arax Advisory Partners first reported a position in PCVX in Q2 2024 and has held it in 8 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Arax Advisory Partners held 393 shares of Vaxcyte worth $22.8K as of Q2 2026.
  • Arax Advisory Partners bought 289 Vaxcyte shares in Q2 2026, an estimated $15.7K.
  • Vaxcyte made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3867 holding.
  • Arax Advisory Partners first reported a position in Vaxcyte in Q2 2024 and has held it in 8 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.